| Literature DB >> 31055052 |
Simone Forcato1, Bruno Garcia Montagnini1, Maria Luiza Marino de Góes1, Daniella Regina Barrionuevo da Silva Novi1, Ana Carolina Inhasz Kiss2, Graziela Scalianti Ceravolo1, Daniela Cristina Ceccatto Gerardin3.
Abstract
Metformin (MET) is a widely-used drug for the treatment of type 2 diabetes mellitus and gestational diabetes. It is known that metformin crosses the placenta and can to be transferred through milk. In vitro studies show that MET decreases gonadotropin-releasing hormone and gonadotropins release in rat neurons, and decreases progesterone and estradiol in rat granulosa cells and androstenedione synthesis in human theca cells. This study evaluated whether MET maternal exposure might interfere with reproductive parameters of female offspring. Wistar female rats were treated with MET 293 mg/kg/day, by gavage, from gestational day (GD) 0 to GD 21 (METG) or GD 0 until lactation day (LD) 21 (METGL). Controls groups received water. An increase in plasmatic estradiol levels was observed during the estrus stage in the METGL group. This result suggests that exposure to MET during gestational and lactational periods might be related to programming in theca and/or granulosa cells during development.Entities:
Keywords: Antidiabetic drug; Estrous cycle; Maternal exposure
Mesh:
Substances:
Year: 2019 PMID: 31055052 DOI: 10.1016/j.reprotox.2019.04.009
Source DB: PubMed Journal: Reprod Toxicol ISSN: 0890-6238 Impact factor: 3.143